2Collen D,Lijnen HR.Tissue-type plasminogen activator:a historical perspective and personal account[J].J Thromb Haemost,2004,2(4):541～546
3Machraoui A,Jager D,Barmeyer J,et al.Efficacy and safety of APSAC in the treatment of acute myocardial infarction[J].Eur Heart J,1992,13(6):818～823
4Wan H,Liu Z,Xia X,et al.A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo[J].Thromb Res,2000,97(3):133～141
5Renatus M,Stubbs MT,Huber R,et al.Catalytic domain structure of vampire bat plasminogen activator:a molecular paradigm for proteolysis without activation cleavage[J].Biochemistry,1997,436(44):13 483～13 493
7Moons L,Vanlinthout I,Roelants I,et al.Toxicology studies with recombinant staphylokinase and with SY 161-P5,a polyethylene glycol-derivatized cysteine-substitution mutant[J].Toxicol Pathol,2001,29(3):285～291
8Perler B.Thrombolyic therapies:the current state of affairs[J].J Endovasc Ther,2005,12(2):224～232
9Nordt TK,Bode C.Thrombolysis:newer thrombolytic agents and their role in clinical medicine[J].Heart,2003,89(11):1 358～1 362
10Inoue T,Yaguchi I,Takayanagi K,et al.A new thrombolytic agent,monteplase,is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction:initial results of the Combining Monteplase with Angioplasty (COMA) trial[J].Am Heart J,2002,144(4):E5
